Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: iana5252 on May 20, 2015, 02:45:08 pm
-
An investigational anti-diabetes drug may be an option for treating non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Researchers conducted a trial of 336 treatment-naive people with type 2 diabetes and an A1C between 7.0 percent and 9.5 percent.
The higher the A1C level, the greater the chance that someone will develop complications as a result of diabetes. People with diabetes are generally advised to shoot for a level lower than 7.0 percent.
Read more:
http://www.hepmag.com/articles/diabetes_NASH_NAFLD_2501_27256.shtml